Atea Pharmaceuticals(AVIR) - 2021 Q2 - Earnings Call Presentation

AT-527 COVID-19 Clinical Development - AT-527 is being evaluated for COVID-19, targeting SARS-CoV-2 RNA polymerase (nsp12), a highly conserved gene [8, 9] - Phase 2 study in hospitalized patients demonstrated rapid reduction in viral load leading to viral clearance [13] - Interim results from the global Phase 2 hospitalized study showed a rapid and sustained decrease in viral load in all evaluable patients [26] - In the Phase 2 hospitalized study, 98% of patients sequenced at baseline had the P323L mutation and responded to AT-527 treatment [24] - The company is conducting a global Phase 3 MORNINGSKY trial for COVID-19 in the outpatient setting, with results anticipated in the second half of 2021 [13, 19] AT-752 Dengue Fever Program - Atea is developing AT-752 for the treatment of Dengue Fever, with Phase 1a SAD completed and MAD initiated [60, 63] Financial Status - Collaboration revenue for the three months ended June 30, 2021, was $60391000, compared to $0 in 2020 [71] - Net income per share attributable to common stockholders (basic) for the three months ended June 30, 2021, was $002, compared to $(099) in 2020 [68] - Cash and cash equivalents were $816460000 as of June 30, 2021, compared to $850117000 as of December 31, 2020 [73] - The company had $8165 million in cash and cash equivalents as of June 30, 2021, with cash runway through 2023 [76]